Mounjaro contains the active ingredient Tirzepatide It is a revolutionary weight-loss injection that offers a clinically proven approach to managing obesity. It was developed by the pharmaceutical company Eli Lilly. It is a single use, once-weekly injectable treatment designed to regulate appetite and metabolism, providing a targeted solution for sustainable weight loss. Mounjaro is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI ≥*0 kg/m2 (obesity) or ≥*7 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition. Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide*1 receptor agonist. It is a first in a new class of treatments for weight loss and works by suppressing appetite, making you feel less hungry,